SNF

Everest Rehabilitation Hospitals Announces Plans to Construct a 40-Bed Physical Rehabilitation Hospital in McKinney, Texas (their 16th location and 2nd in DFW).

Retrieved on: 
Tuesday, March 19, 2024
Central Expressway, Environment, Television, Patient, SNF, Dallas–Fort Worth metroplex, Brain, Stroke, Hospital, Trauma, Rehabilitation, Quality of life, City, Amputation, Physician, Health

DALLAS and MCKINNEY, Texas, March 19, 2024 /PRNewswire-PRWeb/ -- Today, Everest Rehabilitation Hospitals announced plans to construct a 40-bed inpatient physical rehabilitation hospital in McKinney, Texas. This will be Everest's second location in the DFW Metroplex.

Key Points: 
  • Everest announces McKinney, TX as its latest location for another modern comprehensive physical rehabilitation hospital.
  • DALLAS and MCKINNEY, Texas, March 19, 2024 /PRNewswire-PRWeb/ -- Today, Everest Rehabilitation Hospitals announced plans to construct a 40-bed inpatient physical rehabilitation hospital in McKinney, Texas.
  • We are thrilled to serve Collin County and the surrounding communities by providing the absolute best physical rehabilitation solution.
  • This newest location will feature Everest's new, two-story, 40-bed physical rehabilitation hospital solution to accommodate ideal locations with smaller site availability in the rapidly growing community of McKinney, Texas.

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Retrieved on: 
Wednesday, March 6, 2024
Radiation, Doctor of Philosophy, Immunotherapy, News, FOLFIRINOX, Growth, CADL, PR, CXCR4, Lead, PRS, Multiple myeloma, Poster, Pancreatic cancer, Gemcitabine, Fast Track, Liver, Incidence, Cancer, City, HSC, Chung, TME, Overalls, FACP, Therapy, Sickle cell disease, Columbia University, MAPK, Immune system, SNF, G-CSF, Woman, AIO, SCD, AACR, PD-1, Conference, TILS, Tumor microenvironment, BioLineRx, Clinical trial, Survival, Oncology, Filgrastim, Collection, American Cancer Society, Caregiver, USD, SWI, MD, Blood, FDA, TSX, Biotechnology, Pancreatic Cancer Action Network, Stem cell, RAS, Valaciclovir, PDAC, Patient, Natalizumab, ONC, PEI, Pharmaceutical industry

Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

Key Points: 
  • Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.
  • The American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are: "About 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer.
  • Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths."
  • Biotech/oncology stocks targeting the growing global pancreatic cancer market have made headlines with recent developments and breakthroughs in treatments.

Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
SNF, Hospital, Hospice, Physician, UnitedHealth Group, GAAP, Patient, Rehabilitation, Conditional sentence, Bank statement, Depreciation, Music

BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023.

Key Points: 
  • BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023.
  • Three-Month Periods Ended December 31, 2023 and 2022
    Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022.
  • Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.
  • In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the fourth quarter and year ended December 31, 2023 results.

TimeSmart.AI Announces Partnership with Leading EHR Provider PointClickCare to Revolutionize Contract Compliance and Clinician Invoicing in Skilled Nursing Facilities

Retrieved on: 
Thursday, March 7, 2024
Technology, Payments, Health Technology, Software, Practice Management, Managed Care, Health, Data Management, Artificial Intelligence, SNF, Medical director, General number field sieve, Entrepreneurship, Risk, Organization, OIG

PointClickCare is widely recognized as the premier solution in the senior living and skilled nursing market.

Key Points: 
  • PointClickCare is widely recognized as the premier solution in the senior living and skilled nursing market.
  • With this integration, TimeSmart.AI is now live in the PointClickCare Marketplace, providing an innovative solution for senior care organizations to improve contract compliance and streamline invoice management processes.
  • This integration with PointClickCare allows senior living and skilled nursing facilities to enhance cost and time efficiency through the comprehensive management of timesheets, invoices, and contracts.
  • Through this integration with PointClickCare, we are poised to make a real difference in senior living healthcare."

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

Retrieved on: 
Tuesday, March 5, 2024
AB, SNF, SAN, Immune system, SWI, Immunotherapy, Blood, TSX, FOLFIRINOX, AIO, TME, Pancreatic Cancer Action Network, PR, TILS, Tumor microenvironment, Patient, Poster, Pancreatic cancer, ONC, PEI, Gemcitabine, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, March 5, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced it has submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab (Tecentriq®) in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). This amendment will be reviewed by the Paul Ehrlich Institute (PEI; Germany's regulatory body) for approval before patient enrollment can begin. The cohort, the fifth of the GOBLET gastrointestinal cancer study, is being supported by the US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer. Evaluation of this novel treatment approach will complement Oncolytics' ongoing development of pelareorep, atezolizumab, gemcitabine, and nab-paclitaxel in PDAC, which is expected to advance to a registrational study later this year.

Key Points: 
  • The cohort, the fifth of the GOBLET gastrointestinal cancer study, is being supported by the US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We are enthusiastic to have the support of PanCAN to expand the evaluation of pelareorep in pancreatic cancer and explore mFOLFIRINOX as another combination that could improve outcomes for patients.
  • Chemotherapies, including either mFOLFIRINOX or gemcitabine and nab-paclitaxel, are the backbone treatment regimens of pancreatic cancer therapy1.
  • Therefore, we are enthusiastic about this new mFOLFIRINOX pancreatic cancer cohort and look forward to enrolling the first patient as soon as possible."

Everest Rehabilitation Hospitals Announces Plans to Construct a 40-Bed Physical Rehabilitation Hospital in Sherman/Denison, Texas (their 16th location and 5th in Texas)

Retrieved on: 
Wednesday, February 14, 2024
SNF, Pharmacy, Hospital, Physician, Quality of life, Stroke, Amputation, US-75, City, Health, Patient, Brain, Rehabilitation, Trauma, Television, Environment

DALLAS and SHERMAN, Texas and DENISON, Texas, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Today, Everest Rehabilitation Hospitals announced plans to construct a 40-bed inpatient physical rehabilitation hospital in Sherman / Denison, Texas – specifically between Sherman and Denison one block east of interstate 75.

Key Points: 
  • Everest announces Sherman/ Denison, TX as its latest location for another modern comprehensive physical rehabilitation hospital.
  • DALLAS and SHERMAN, Texas and DENISON, Texas, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Today, Everest Rehabilitation Hospitals announced plans to construct a 40-bed inpatient physical rehabilitation hospital in Sherman / Denison, Texas – specifically between Sherman and Denison one block east of interstate 75.
  • This newest location will feature Everest's new, two-story, physical rehabilitation hospital solution to accommodate the smaller site availability in the rapidly growing communities of Sherman / Denison.
  • The physical rehabilitation hospital will be constructed on 1.94 acres conveniently located next door to the 414-bed Texoma Medical Center Hospital off of US-75 and Grayson Drive.

United States Home Care Market Analysis Report 2023: Higher Acuity Home-Based Care Is A Top Priority For Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 31, 2024
Managed Care, Health, Other Health, RPM, Software, Home, Conditional sentence, Acceleration, Ageing, Patient, SNF, PHE, CMS, DME, Data collection, Medicare, Hospital

The "2023 United States Home Care Market Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2023 United States Home Care Market Report" report has been added to ResearchAndMarkets.com's offering.
  • The home care market is valued at $264.3 billion in 2023.
  • By 2025, between ten and 25% of care delivered in hospitals, outpatient clinics, physician offices, skilled nursing facilities, and urgent care is projected to shift to the home.
  • The market includes home-based medical care, hospice, home care and personal services, and durable medical equipment (DME).

Signature HealthCARE’s President and CEO Receives Notable Honor: McKnight’s 2024 Pinnacle Thought Leader Award

Retrieved on: 
Tuesday, January 2, 2024
Partnership, COVID-19, Classification, Movement, International Center, Health, Population health, Long-term care, American Securities, Commerce, News, Entrepreneurship, Innovation, University of Pennsylvania, Workplace, SNF, Medicare, Assisted living, Institution, Growth, QAPI, Nursing, Publication, Accreditation, HITC, University

For the last 30+ years, it is this kind of revolutionary thinking from Signature HealthCARE’s President and CEO, E. Joseph Steier, III that has garnered him the notable honor of being named as a McKnight’s Pinnacle Thought Leader Award recipient for 2024.

Key Points: 
  • For the last 30+ years, it is this kind of revolutionary thinking from Signature HealthCARE’s President and CEO, E. Joseph Steier, III that has garnered him the notable honor of being named as a McKnight’s Pinnacle Thought Leader Award recipient for 2024.
  • Established Signature HealthCARE as a top 10 post-acute healthcare organization with all Chief Operational leaders trained and certified as CNAs.
  • Co-founding the Signature Inspire Foundation, the non-for-profit philanthropic arm of Signature HealthCARE with its CNA-directed Board.
  • Signature HealthCARE has also been awarded a Best Places to Work in Kentucky honor by the Kentucky Chamber of Commerce, for six years.

OptimumBank Holdings, Inc. (OPHC-NASDAQ) Chairman Gubin’s comments pertaining to the Board’s Strategic Planning - “A successful roadmap for growing our Bank”

Retrieved on: 
Friday, December 8, 2023
Loan, Small Business Administration, Growth, SNF, Management, NIM, SBA, Net interest margin, Bank

The net change in total assets was partially driven by a $26 million increase in net loans.

Key Points: 
  • The net change in total assets was partially driven by a $26 million increase in net loans.
  • Since the Company announced entry into Accounts Receivable Financing to Skilled Nursing Facilities at the end of last year, our SNF portfolio has grown to over $28MM.
  • Growing the asset size of the Company for the remainder of 2023 and into 2024 is facilitating our goal to provide greater shareholder returns.
  • OptimumBank’s strategic plan also encompasses expanding lending capabilities, increasing the Company’s core deposit base primarily with fee-based income businesses and by evaluating M&A opportunities.

Bamboo Health Launches Discharge Summaries to Help Ensure Patients Receive Timely, Appropriate Care After Leaving the Hospital

Retrieved on: 
Monday, November 13, 2023
Nursing, Data Management, Practice Management, Technology, Managed Care, Health, General Health, Mental Health, Health Technology, Software, Hospitals, Human, EHR, Nursing home, Discharge, Admission, Transition, Patient, TCM, Caregiver, Communication, Triad, SNF, ADT, Ping, Environmental remediation, Health insurance

Bamboo Health ™ today announced its latest innovation, Discharge Summaries , an enhancement to the company’s existing nationwide Pings platform.

Key Points: 
  • Bamboo Health ™ today announced its latest innovation, Discharge Summaries , an enhancement to the company’s existing nationwide Pings platform.
  • "Discharge Summaries has been a game-changer for our network, especially for the coordination in the continuum.
  • Bamboo Health's Discharge Summaries offers game-changing advantages:
    Seamless Access: Care coordinators can effortlessly obtain discharge information, avoiding the detective work and phone calls needed to manually track down missing summaries.
  • With Bamboo Health's Discharge Summaries, healthcare organizations can now ensure a smoother transition for patients, enhancing quality, cost and satisfaction.